Beijing Tiantan Biological Products Corp Ltd Total Assets
Beijing Tiantan Biological Products Corp Ltd total assets. Based on the latest financial reports, Beijing Tiantan Biological Products Corp Ltd (600161) holds total assets worth CN¥16.55 Billion CNY (≈ $2.42 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Beijing Tiantan Biological Products Corp (600161) total market value for the company's overall valuation and market capitalisation.
Total Assets of Beijing Tiantan Biological Products Corp Ltd (1995–2024)
Total assets of Beijing Tiantan Biological Products Corp Ltd from 1995 to 2024. This chart illustrates how Beijing Tiantan Biological Products Corp Ltd's total assets have evolved over time, based on quarterly financial data. See Beijing Tiantan Biological Products Corp (600161) stock price for real-time trading data and today's change.
Beijing Tiantan Biological Products Corp Ltd - Asset Composition Analysis
Beijing Tiantan Biological Products Corp Ltd Total Assets Breakdown (December 2024)
Beijing Tiantan Biological Products Corp Ltd total assets breakdown as of December 2024. Beijing Tiantan Biological Products Corp Ltd's total assets of CN¥16.55 Billion consist of 48.7% current assets and 51.3% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 16.9% |
| Accounts Receivable | CN¥1.13 Billion | 7.2% |
| Inventory | CN¥3.87 Billion | 24.4% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥1.31 Billion | 8.2% |
| Goodwill | CN¥572.15 Million | 3.6% |
Asset Composition Trend (1995–2024)
This chart illustrates how Beijing Tiantan Biological Products Corp Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 600161 current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Beijing Tiantan Biological Products Corp Ltd's current assets represent 48.7% of total assets in 2024, a decrease from 61.2% in 1995.
- Cash Position: Cash and equivalents constituted 16.9% of total assets in 2024, down from 17.4% in 1995.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, an increase from 0.0% in 1995.
- Asset Diversification: The largest asset category is inventory at 24.4% of total assets.
Beijing Tiantan Biological Products Corp Ltd Competitors by Total Assets
Key competitors of Beijing Tiantan Biological Products Corp Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
ACADIA Pharmaceuticals Inc
NASDAQ:ACAD
|
USA | $1.74 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
|
INVENTIVA ADS/1 O.N.
F:6IVA
|
Germany | €249.51 Million |
|
PYC Therapeutics Ltd
AU:PYC
|
Australia | AU$183.28 Million |
Beijing Tiantan Biological Products Corp Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.01 | 5.51 | 4.96 |
| Quick Ratio | 3.08 | 3.31 | 2.64 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥6.90 Billion | CN¥6.99 Billion | CN¥3.72 Billion |
Beijing Tiantan Biological Products Corp Ltd - Advanced Valuation Insights
This section examines the relationship between Beijing Tiantan Biological Products Corp Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.85 |
| Latest Market Cap to Assets Ratio | 0.23 |
| Asset Growth Rate (YoY) | 11.9% |
| Total Assets | CN¥15.87 Billion |
| Market Capitalization | $3.62 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Beijing Tiantan Biological Products Corp Ltd's assets below their book value (0.23x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Beijing Tiantan Biological Products Corp Ltd's assets grew by 11.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Beijing Tiantan Biological Products Corp Ltd (1995–2024)
The table below shows the annual total assets of Beijing Tiantan Biological Products Corp Ltd from 1995 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥15.87 Billion ≈ $2.32 Billion |
+11.85% |
| 2023-12-31 | CN¥14.19 Billion ≈ $2.08 Billion |
+9.64% |
| 2022-12-31 | CN¥12.94 Billion ≈ $1.89 Billion |
+11.77% |
| 2021-12-31 | CN¥11.58 Billion ≈ $1.69 Billion |
+53.53% |
| 2020-12-31 | CN¥7.54 Billion ≈ $1.10 Billion |
+19.43% |
| 2019-12-31 | CN¥6.31 Billion ≈ $924.00 Million |
+24.62% |
| 2018-12-31 | CN¥5.07 Billion ≈ $741.46 Million |
+38.22% |
| 2017-12-31 | CN¥3.67 Billion ≈ $536.41 Million |
-36.61% |
| 2016-12-31 | CN¥5.78 Billion ≈ $846.27 Million |
+2.69% |
| 2015-12-31 | CN¥5.63 Billion ≈ $824.13 Million |
-6.38% |
| 2014-12-31 | CN¥6.02 Billion ≈ $880.25 Million |
+6.76% |
| 2013-12-31 | CN¥5.63 Billion ≈ $824.51 Million |
+17.24% |
| 2012-12-31 | CN¥4.81 Billion ≈ $703.28 Million |
+49.07% |
| 2011-12-31 | CN¥3.22 Billion ≈ $471.78 Million |
+31.70% |
| 2010-12-31 | CN¥2.45 Billion ≈ $358.23 Million |
+13.28% |
| 2009-12-31 | CN¥2.16 Billion ≈ $316.23 Million |
+80.64% |
| 2008-12-31 | CN¥1.20 Billion ≈ $175.06 Million |
+9.26% |
| 2007-12-31 | CN¥1.09 Billion ≈ $160.22 Million |
+2.85% |
| 2006-12-31 | CN¥1.06 Billion ≈ $155.78 Million |
+25.42% |
| 2005-12-31 | CN¥848.76 Million ≈ $124.20 Million |
+11.31% |
| 2004-12-31 | CN¥762.49 Million ≈ $111.58 Million |
+0.47% |
| 2003-12-31 | CN¥758.95 Million ≈ $111.06 Million |
+50.36% |
| 2002-12-31 | CN¥504.77 Million ≈ $73.86 Million |
+8.95% |
| 2001-12-31 | CN¥463.32 Million ≈ $67.80 Million |
+3.89% |
| 2000-12-31 | CN¥445.98 Million ≈ $65.26 Million |
+1.46% |
| 1999-12-31 | CN¥439.55 Million ≈ $64.32 Million |
+16.18% |
| 1998-12-31 | CN¥378.34 Million ≈ $55.36 Million |
+140.60% |
| 1997-12-31 | CN¥157.25 Million ≈ $23.01 Million |
+18.01% |
| 1996-12-31 | CN¥133.25 Million ≈ $19.50 Million |
+6.73% |
| 1995-12-31 | CN¥124.85 Million ≈ $18.27 Million |
-- |
About Beijing Tiantan Biological Products Corp Ltd
Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, sale, and marketing of blood products in China and internationlly. Its products include human albumin; intravenous human immunoglobulin; rabies patient immunoglobulin; tetanus human immunoglobulin; hepatitis B human immunoglobulin; freeze-dried intravenous hepatitis B human immunoglobulin; histamin… Read more